Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
Tackling the Inevitability of Resistance One Genome at a Time
Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
Quicker Development and Investing
Congress appears poised this year to deliver on years of lobbying by industry to speed up reviews of new drugs and cut regulatory red tape. Chief among several related bills is the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). Faster action on drug applications is the goal of the Faster Access to Specialized Treatments (FAST) Act introduced in the House of Representatives, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act introduced in the Senate, and another Senate bill, the Advancing Breakthrough Therapies for Patients Act of 2012. The impact of these legislations would be seen in the Phase II and III stage and less so in the valley of death.